News & Views
Deal Secures Supply of Essential Biologicals
Mar 18 2019
Germany-based BioNTech (Mainz), a company focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates, has signed a multi-year agreement with Thermo Fisher Scientific for the supply of nucleotides, enzymes and other materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.
"Our portfolio of molecular biology products is now enabling development and commercialisation of multiple individualised therapies and other advanced medicines and we continue to expand our capabilities to meet increasing demand," said Gianluca Pettiti, president, biosciences, Thermo Fisher Scientific. "We share BioNTech's commitment to deliver life-saving therapies to patients faster and we look forward to supporting them through clinical trials and post-approval production."
"The relationship with Thermo Fisher Scientific secures our access to customised material essential for the manufacturing and commercialisation of our RNA-based product candidates," said Ugur Sahin, managing director, co-founder and CEO of BioNTech. "In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities."
No other terms from this transaction were disclosed.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan